超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Atossa Genetics
我們的第一個產品和服務是乳腺細胞吸取器檢測(MASCTSystem?). 這個已經美國國家食品衛生檢驗局許可的取樣及細胞測試系統只需10 分鐘的取樣，且是無痛的。此項檢測可提早幾年偵測癌變細胞。

我們透過研究及開發，推出的創新產品和服務來協助醫護人員維持女性健康和福利。進而預防、診斷及治療包括癌癥有關乳房的疾病。

我們是一家醫療保健公司專注于開發和銷售為乳腺癌風險評估的新型細胞和分子診斷產品。

We are a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.

Using our patented, FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes. The NAF sample contains cells (cytology) and molecular diagnostic biomarkers that are useful in finding cancers and pre-cancerous changes, especially Atypical Ductal Hyperplasia (ADH), which confers a higher risk of developing breast cancer.

The FDA has determined, based on clinical trial data, that the MASCT System can be used in the determination and/or differentiation of normal versus premalignant versus malignant cells. Cytology changes in NAF have been shown to occur up to eight years before changes can be picked up by mammography.

Our name comes from Atossa, daughter of Cyrus the Great and wife of Darius I, the King of the Achaemenid Empire. In about 470 BC she became the first woman in recorded history to be diagnosed with breast cancer.